DI

Debiopharm Innovation Fund at BioTechX Europe 2026

Oct 6–8, 2026 Basel, Switzerland ~3k attendees Website

Debiopharm Innovation Fund takes part in 2 sessions at BioTechX Europe 2026 in Basel. Its program is about investing in AI for life sciences, including recent AI investment trends discussed with Science Capital Ventures, Ambrosia Ventures and Wellcome Genome Campus. It also makes the case for a new strategic role for pharma corporate venture capital, the investment funds that drug companies run.

OrganizationBioTechX Europe 2026 Attendance
DI
Debiopharm Innovation Fund
Lausanne, Switzerland
Other services
Corporate venture capital fund of the Swiss biopharmaceutical group Debiopharm.
Talk
Tue Oct 6
15:30
A new strategic role for pharma CVC
AI in Clinical Trials
Keynote
Thu Oct 8
09:25
Investment trends in AI
Keynotes · with Science Capital Ventures, Ambrosia Ventures, Wellcome Genome Campus +1 more
AI & large language models

Explore the full BioTechX Europe 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Basel. Leave your work email and we’ll be in touch.

Privacy

Download the full BioTechX Europe 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Debiopharm Innovation Fund

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by Terrapinn or BioTechX. Submit a correction